Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Author:

Millot Frédéric1,Guilhot Joelle1,Baruchel André2,Petit Arnaud3,Bertrand Yves4,Mazingue Françoise5,Lutz Patrick6,Vérité Cecile7,Berthou Christian8,Galambrun Claire9,Sirvent Nicolas10,Yakouben Karima11,Schmitt Claudine12,Gandemer Virginie13,Reguerre Yves14,Couillault Gérard15,Mechinaud Françoise16,Cayuela Jean-Michel17

Affiliation:

1. Centre d’Investigation Clinique 1402 INSERM, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;

2. Pediatric Department, Assistance Publique–Hôpitaux de Paris and University Paris Diderot, Assistance Publique-Hôpital Saint Louis and Robert Debré, Paris, France;

3. Hematology Unit, Hôpital Trousseau, Paris, France;

4. Hematology Unit, Institut d’Hématologie et d’Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon, France;

5. Pediatric Oncology Unit, University Hospital, Lille, France;

6. Pediatric Oncology Unit, University Hospital, Strasbourg, France;

7. Pediatric Oncology Unit, University Hospital, Bordeaux, France;

8. Hematology Department, University Hospital, Brest, France;

9. Hematology Unit, University Hospital, Marseille, France;

10. Pediatric Oncology Unit, University Hospital, Montpellier, France;

11. Hematology Unit, Hôpital Robert Debré, Paris, France;

12. Hematology Unit, University Hospital, Nancy, France;

13. Pediatric Oncology Unit, University Hospital, Rennes, France;

14. Pediatric Oncology Unit, University Hospital, Angers, France;

15. Pediatric Oncology Unit, University Hospital, Dijon, France;

16. Pediatric Oncology Unit, University Hospital, Nantes, France; and

17. Laboratory of Molecular Hematology, University Hospital Saint-Louis, Assistance Publique–Hôpitaux de Paris and EA3518 Unit, University Paris Diderot, Paris, France

Abstract

Key Points Early molecular response at 3 months can predict outcome in children treated with imatinib for CML. Children with CML may be less likely to achieve an early molecular response to imatinib than adults with CML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3